Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
Study Details
Study Description
Brief Summary
The purpose of this study is to differentiate between the administrations of Cetuximab alone vs. Cetuximab plus Docetaxel in the treatment of non-metastatic prostate cancer before the surgical removal of the prostate.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
With the larger number of men who undergo screening with assays for serum prostate specific antigen, urologists continue to see considerable numbers of patients with locally advanced prostate disease. There is a higher risk of treatment failure in any patient with a tumor that extends through the prostate capsule, more aggressive pathology (Gleason score of 7 or higher), or patients with a PSA of greater than 10 ng/ml. The rationale for adding molecular targeted drugs such as Cetuximab (epithelial growth factor inhibitor), with or without chemotherapy such as Docetaxel, is that such therapy has the potential to demonstrate tumor shrinkage of the prostate and, in addition, micrometastatic cells. Cetuximab alone or Cetuximab plus Docetaxel utilizing the preprostatectomy model, with the adjuvant delivery of
Cetuximab for 6 months, will provide data for the following points:
-
demonstration of a PSA response prior to prostatectomy;
-
demonstration whether a change in the natural history, with a delay in the onset of metastatic disease in patients with advanced local prostate cancer, can be achieved;
-
laboratory and tissue correlation to assess changes in proliferative, apoptosis, and pathologic parameters; and
-
metabolic imaging utilizing CT-PET with FDG to assess whether this will be a useful modality in exhibiting a response to therapy, compared with conventional radiographic imaging.
This will provide the basis for future development of neoadjuvant chemotherapy prior to prostatectomy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Data not available PI relocated No verifiable data available, PI relocated |
Drug: cetuximab
No verifiable data available, PI relocated
Other Names:
Drug: docetaxel
No verifiable data available, PI relocated
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Pathological response (prostate biopsy vs. prostatectomy specimen pathological evaluation): done pre-treatment vs. after prostatectomy at Week 10 [during study]
No verifiable data available, PI relocated
- Clinical response: digital rectal exam pre-treatment and q 6 months after prostatectomy [during study]
No verifiable data available, PI relocated
Secondary Outcome Measures
- PSA response: tested q 3 weeks pre-prostatectomy and q 6 months post-prostatectomy [during study]
No verifiable data available, PI relocated
- Correlation with MRI and nuclear imaging: scans pre-treatment vs. Week 10 before surgery and yearly when PSA > 0.3 [during study]
No verifiable data available, PI relocated
- Correlation with metabolic imaging (PET with FDG): scans pre-treatment vs. Week 10 before surgery [during study]
No verifiable data available, PI relocated
- Correlation with serum and plasma for antiangiogenic factors: tested q 3 weeks pre-prostatectomy [during study]
No verifiable data available, PI relocated
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologic proof of prostatic adenocarcinoma without evidence of regional and/or distant metastasis, clinical stage T1c or T2a with high grade disease (Gleason's 8-10) on initial biopsy, or clinical stage T2b-T2c with Gleason's grade 7 or above with a PSA ≥ 10ng/ml, or clinical stage T3.
-
Recent (< 6 weeks prior to study entry) negative bone scan and MRI of abdomen and pelvis.
-
Appropriate surgical candidate for radical prostatectomy and a performance status of < 2 (Zubrod scale).
-
Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count > 1,500 and platelet count of > 100,000, adequate hepatic function with a bilirubin < 1.5 mg % and SGPT < 2.5x the upper limits of normal, adequate renal function defined as serum creatinine < 1.5 x ULN.
-
Patients must have normal coagulation profile (PT, PTT) and no history of substantial non-iatrogenic bleeding diatheses. Use of anticoagulants is limited to local use only (for control of central line patency).
-
Patients must have no history of congestive heart failure or previous MI within the last 12 months.
Exclusion Criteria:
-
Previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy or other investigational status drug.
-
Unable to tolerate transrectal ultrasound.
-
Patients who are not appropriate surgical candidates for radical prostatectomy based on the evaluation of co-existent medical diseases and competing causes of death. Patients with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorder are not eligible. Patients with uncontrolled and symptomatic orthostatic hypotension or uncontrolled hypertension are not eligible.
-
Patients who are HIV positive or have chronic hepatitis B or C infections are not eligible.
-
Patients on oral steroid medications are not eligible.
-
Patients with significant arteriosclerotic disease, as defined by a previous arterial bypass claudication limiting activity, or a history of cerebrovascular events within the last year (including TIA) are not eligible.
-
Prior severe infusion reaction to a monoclonal antibody.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Baylor College of Medicine - Methodist Hospital | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- The Methodist Hospital Research Institute
- Bristol-Myers Squibb
- Eli Lilly and Company
Investigators
- Principal Investigator: Robert J Amato, DO, Baylor College of Medicine - Methodist Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
- HMRI IRB#0206-0027
- E-VS-ET-2006